Comparison of outcomes after HLA-matched and haploidentical HSCT for MM

0
0
0

Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma
Yao Chen1, Wei-Jun Fu2, Lan-Ping Xu1, Han-Yun Ren3, Yong-Rong Lai4, Dai-Hong Liu5, Lin Liu6, Zi-Min Sun7, Yuan-Bin Wu8, Xin Wang9, Ling-Hui Xia10, Ming Jiang11, Tong-Lin Hu12, Ding-Ming Wan13, Xiao-Jun Huang1,14
1Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; 2Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China; 3Department of Hematology, Peking University First Hospital, Beijing 100034, China; 4Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China; 5Department of Hematology, Chinese People’s Liberation Army General Hospital, Beijing 100853, China; 6Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China; 7Department of Hematology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, China; 8Department of Hematology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510530, China; 9Department of Hematology, Shandong Provincial Hospital, Jinan, Shandong 250021, China; 10Department of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; 11Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University; Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, Xinjiang 830054, China; 12Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Zhejiang International Exchange Center of Clinical Traditional Chinese Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China; 13Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China; 14Peking-Tsinghua Center for Life Sciences, Beijing 100871, China

Multiple myeloma (MM) is the second most common blood cancer, with over 30,000 new cases diagnosed in the U.S. each year and millions living with the disease worldwide. For patients with relapsed, refractory, or ultra-high-risk MM, allogeneic stem cell transplantation (allo-SCT)—a procedure where donor stem cells replace the patient’s cancerous blood cells—offers a unique benefit: the “graft-vs.-myeloma effect,” where donor cells attack remaining cancer cells. But finding a matched donor—someone with identical human leukocyte antigen (HLA) markers, often a sibling—is only possible for ~30% of patients. Haploidentical donors—family members who share half the HLA markers (e.g., parents, children, or siblings)—provide a critical alternative. A new multicenter study from China tests whether haploidentical transplants work as well as matched sibling transplants for MM.

Study Overview

Led by researchers from Peking University People’s Hospital and 12 other Chinese hospitals, the study analyzed data from 97 MM patients who received myeloablative allo-SCT (high-dose chemotherapy/radiation to kill cancer cells before transplant) between 2001 and 2017. Seventy patients had transplants from matched siblings (MRD group), while 27 had transplants from haploidentical family members (haplo group). To ensure fair comparisons, each haplo patient was matched to a MRD patient based on three factors:

  1. Transplant year (within 2 years),
  2. Disease status at transplant (e.g., remission or active disease),
  3. Follow-up length.

Key Terms to Know

Before diving into results, here’s a quick primer on transplant-related terms:

  • Engraftment: When donor stem cells start making healthy blood cells (neutrophils for infection defense, platelets for clotting).
  • Graft-vs.-host disease (GVHD): A side effect where donor cells attack the patient’s healthy tissues (acute = within 100 days; chronic = after 100 days).
  • Non-relapse mortality (NRM): Death from causes other than MM (e.g., infection, GVHD).
  • Progression-free survival (PFS): Time from transplant until cancer worsens or the patient dies.
  • Overall survival (OS): Time from transplant until the patient dies from any cause.
  • 95% confidence interval (CI): A range where the true result likely falls (e.g., a 10–30% NRM rate means researchers are 95% sure the real number is between 10% and 30%).

What the Study Found

The results, published in the Chinese Medical Journal, show haploidentical transplants are just as safe and effective as matched sibling transplants for eligible MM patients:

1. Engraftment: Donor Cells Take Root Successfully

Nearly all patients in both groups achieved engraftment (healthy blood cell production):

  • Neutrophil recovery: 94.3% of MRD patients (95% CI 88.8–99.8%) and 92.3% of haplo patients (95% CI 82.1–100%) had enough infection-fighting neutrophils within 21 days.
  • Platelet recovery: 97.0% of MRD patients (95% CI 92.9–100%) and 92.3% of haplo patients (95% CI 82.1–100%) had enough clotting platelets within 60 days. While platelet recovery was slightly lower in the haplo group, it was still very high—and successful for most patients.

2. GVHD: Acute Risk Is Similar; Chronic GVHD Is Higher in Haplo Patients

  • Acute GVHD (grades 2–4): 29.2% of MRD patients (95% CI 18.0–40.4%) and 23.0% of haplo patients (95% CI 6.9–39.1%) developed moderate-to-severe acute GVHD within 100 days.
  • Chronic GVHD: 28.4% of MRD patients (95% CI 14.7–42.1%) and 77.9% of haplo patients (95% CI 52.4–100%) developed chronic GVHD within 3 years. While higher, this didn’t lead to more deaths—suggesting chronic GVHD may reflect a stronger graft-vs.-myeloma effect (donor cells fighting cancer).

3. Survival: Donor Type Doesn’t Affect Outcomes

The most important predictor of success was disease status at transplant—not donor type. Patients in partial or complete remission (PR/CR) before transplant had better outcomes. For all other patients, haploidentical and matched sibling transplants performed similarly:

  • Non-relapse mortality (NRM): At 1 year, 20.5% of MRD patients (95% CI 10.9–30.1%) and 16.8% of haplo patients (95% CI 1.7–31.9%) died from non-cancer causes. At 3 years, NRM was 24.2% (MRD, 95% CI 13.8–34.6%) vs. 28.7% (haplo, 95% CI 8.7–48.7%)—no significant difference.
  • Relapse: At 3 years, 44.4% of MRD patients (95% CI 30.7–58.1%) and 57.6% of haplo patients (95% CI 33.7–81.5%) had their MM return—no significant difference.
  • Progression-free survival (PFS): At 1 year, 59.8% of MRD patients (95% CI 48.2–71.4%) and 65.6% of haplo patients (95% CI 47.2–84.0%) were alive without cancer progression. At 3 years, PFS was 45.4% (MRD, 95% CI 33.4–57.4%) vs. 26.8% (haplo, 95% CI 7.6–46.0%)—no significant difference.
  • Overall survival (OS): At 1 year, 72.8% of MRD patients (95% CI 62.4–83.2%) and 68.8% of haplo patients (95% CI 50.8–86.8%) were alive. At 3 years, OS was 60.1% (MRD, 95% CI 48.3–71.9%) vs. 37.5% (haplo, 95% CI 15.9–59.1%)—no significant difference.

What This Means for MM Patients

These results are a game-changer for patients who can’t find a matched donor:

  • Haploidentical transplants are safe: NRM rates (16.8–28.7%) align with recent studies showing improved transplant safety (down from 40–60% in the 1990s).
  • Disease control before transplant matters most: Patients in remission (PR/CR) have better outcomes—regardless of donor type. This reinforces the need for aggressive pre-transplant treatment to reduce tumor burden.
  • Chronic GVHD may be a silver lining: While chronic GVHD is a side effect, it may signal a stronger graft-vs.-myeloma effect. More research is needed, but this is a hopeful sign for long-term cancer control.

Limitations to Consider

Like all retrospective studies, this one has constraints:

  • Small haplo group: Only 27 patients received haploidentical transplants—larger studies are needed to confirm results.
  • Varying treatments: Conditioning regimens and post-transplant care changed over the 16-year study period, which may affect outcomes.
  • Missing data: Some patients lacked complete genetic (cytogenetic) or disease stage information.

Conclusion

For MM patients without a matched donor, haploidentical transplants are a safe, effective alternative to matched sibling transplants. The study found no significant differences in survival, relapse, or non-relapse mortality between the two groups—meaning haploidentical donors can save lives.

The biggest takeaway? Get to remission before transplant. Patients who control their disease first have better outcomes. And while relapse remains a risk (44–58% at 3 years), advances in post-transplant maintenance (e.g., immunomodulatory drugs, proteasome inhibitors) and minimal residual disease (MRD) monitoring (to catch relapse early) are giving patients more tools to fight back.

This study was published in the Chinese Medical Journal in 2019 by Yao Chen, Wei-Jun Fu, Lan-Ping Xu, and colleagues from 13 Chinese hospitals. The full paper is available at doi.org/10.1097/CM9.0000000000000341.

Was this helpful?

0 / 0